COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PGD2 Formation in Vascular Injury (PGD2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01001260
Recruitment Status : Terminated (Unable to find subjects that met inclusion/exclusion criteria.)
First Posted : October 26, 2009
Last Update Posted : June 11, 2019
Information provided by (Responsible Party):
University of Pennsylvania

Brief Summary:
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

Condition or disease Intervention/treatment
Coronary Artery Disease Acute Coronary Syndrome Stable Angina Drug: No ASA Drug: Low dose ASA Drug: 325 mg ASA

Detailed Description:

A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans

B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.

Layout table for study information
Study Type : Observational
Actual Enrollment : 51 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Biosynthesis of PGD2 in Vascular Injury
Study Start Date : August 2007
Actual Primary Completion Date : February 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Aspirin

Group/Cohort Intervention/treatment
No Aspirin Treatment Drug: No ASA
Alternative antiplatelet therapy instead of aspirin

81 mg Aspirin Treatment Drug: Low dose ASA
Low dose aspirin (81mg) prior to PTCA

325 mg Aspirin Drug: 325 mg ASA
high dose of aspirin prior to PTCA

Primary Outcome Measures :
  1. The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite. [ Time Frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection. ]

Secondary Outcome Measures :
  1. Whether aspirin could blunt the increment of PGD2 if there is. [ Time Frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection. ]

Biospecimen Retention:   Samples With DNA
  • Specimens:

    3 urine collections will be obtained (Prior to PTCA, During PTCA and Post PTCA)

  • Genetic Testing:

analysis of the association of SNPs in Cox genes with variability in selectively or in the PGEs genes in quantitative biosynthesis of PGD2 and related compounds.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients scheduled to have PTCA

Inclusion Criteria:

  • Patients with existing CAD admitted for elective PTCA:

    1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or
    2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or
    3. No aspirin therapy at all
  • Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA
  • Patients with stable angina or positive stress tests scheduled for a cardiac catheterization

Exclusion Criteria:

  • History of unstable diabetes (hgb A1c>8 or FBS> 200)
  • Uncontrolled hypertension (SBP > 180, DBP >100)
  • History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.
  • Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01001260

Sponsors and Collaborators
University of Pennsylvania
Layout table for investigator information
Principal Investigator: Garret FitzGerald, MD University of Pennsylvania
Principal Investigator: Wenliang Song, MD University of Pennsylvania
Layout table for additonal information
Responsible Party: University of Pennsylvania Identifier: NCT01001260    
Other Study ID Numbers: 804975
American Heart Association
First Posted: October 26, 2009    Key Record Dates
Last Update Posted: June 11, 2019
Last Verified: June 2019
Keywords provided by University of Pennsylvania:
vascular injury
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Acute Coronary Syndrome
Angina, Stable
Vascular System Injuries
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Angina Pectoris
Chest Pain
Neurologic Manifestations
Wounds and Injuries
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors